Skip to main content
Premium Trial:

Request an Annual Quote

New Releases: Apr 22, 2009

Premium

AltheaDx this week announced the launch of its Affymetrix Drug Metabolizing Enzymes & Transporter genotyping microarray service.

According to the company, the new service provides biopharmaceutical clients with "a way to measure the genetics of drug metabolism in clinical trial patients — giving drug developers the opportunity to select patients that are more likely to respond."

AltheaDx will compile patients' genetic data in a report for customers, and this information can then be integrated into existing clinical trial protocols.

"The DMET report includes biomarker analysis from all US Food and Drug Administration-validated genes and more than 150 well-documented biomarkers known to impact drug metabolism," the company said in a statement. "In addition to these proven biomarkers, the report contains information on a total of 1,936 genetic variants in 225 enzyme and transporter genes, making it a useful tool for exploratory pharmacokinetic studies to identify new biomarkers such as variants in CYP4F2, recently discovered using DMET to explain 8 percent of warfarin dosing variability."

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.